Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Luye Pharma Group ( (HK:2186) ) is now available.
Luye Pharma Group has enrolled the first subject in a U.S. pharmacokinetic bridging trial for its in-house innovative drug LY03015, the first investigational therapy designed to both inhibit VMAT2 and activate sigma-1 receptors for treating tardive dyskinesia and Huntington’s disease. The open-label study in healthy Chinese and Caucasian adults will generate safety and PK data to guide dose selection for planned Phase II and III trials in the U.S., supporting parallel development with an ongoing Phase II in China and reinforcing Luye’s push to strengthen its competitive positioning in CNS disorders where current VMAT2 inhibitors leave a substantial unmet medical need.
The most recent analyst rating on (HK:2186) stock is a Buy with a HK$5.00 price target. To see the full list of analyst forecasts on Luye Pharma Group stock, see the HK:2186 Stock Forecast page.
More about Luye Pharma Group
Luye Pharma Group is a Bermuda-incorporated biopharmaceutical company with a strategic focus on the central nervous system (CNS) therapeutic area. The Group has built a differentiated portfolio spanning depression, schizophrenia, bipolar disorder and Alzheimer’s disease, with marketed products in the U.S., Japan, China and Europe, and multiple CNS drug candidates in clinical development.
YTD Price Performance: 10.58%
Average Trading Volume: 22,857,217
Technical Sentiment Signal: Sell
Current Market Cap: HK$11.9B
For detailed information about 2186 stock, go to TipRanks’ Stock Analysis page.